I think they have tried with a few announcements, but it seems like the market is just losing interest.From my perspective, I would like to see more metrics like revenue retention rate and lifetime value to customers acquisition cost.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%